Company news
Shanghai Shyndec Pharmaceutical Co., Ltd. Class A (SSE:600420) news
Shanghai Shyndec Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: (600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement…
Press releases & updates
(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate
September 29, 2026
"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Progress of Provision of Guarantees by a Wholly-owned Subsidiary to Its Subordinate Enterprise
September 11, 2026
"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Implementation of Dividend Distribution for the First Half of 2026
September 10, 2026
"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing
September 2, 2026
"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on the Wholly-Owned Subsidiary's Receipt of the Approval Notice for the Marketing Application of a Chemical API
August 27, 2026
"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Resolutions of the 8th Meeting of the 9th Board of Directors
August 26, 2026
"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
August 19, 2026
"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Wholly-owned Sub-subsidiary Obtaining Approval for Marketing of Chemical APIs
August 4, 2026
"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Resolutions of the 6th Meeting of the 9th Board of Directors
August 3, 2026
"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Progress of Signing of the "Drug Marketing Authorization Transfer Contract" by a Controlled Subsidiary
July 30, 2026
"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate by Wholly-owned Subsidiary
July 24, 2026
"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate
July 23, 2026
"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on the Wholly-owned Subsidiary's Drug Passing Generic Drug Consistency Evaluation
July 13, 2026
"Shanghai Shyndec Pharmaceutical Co., Ltd."Semi-annual Performance Forecast for 2026
July 10, 2026
"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Resolutions of the 5th Meeting of the 9th Board of Directors
June 30, 2026
Announcement on Holding Subsidiary Obtaining Drug Registration Certificate
June 25, 2026
Announcement on Obtaining Drug Registration Certificate by Subsidiary
June 23, 2026
Announcement on Implementation of Dividend Distribution for 2025
May 25, 2026
Announcement on Obtaining Drug Registration Certificate
May 21, 2026
Announcement on Wholly-owned Subsidiary's Drug Substance Obtaining Indian Registration Certificate
May 11, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 8, 2026
Report for Q1 2026
April 29, 2026
Announcement on Progress in Providing Guarantees for Subsidiaries
April 15, 2026
Earnings Preannouncement for Q1 2026
April 10, 2026
Announcement on Voluntary Information Disclosure of Wholly-owned Subsidiary's Drug Passing Consistency Evaluation for Generic Drugs
April 3, 2026
Announcement on Estimated Daily Related Party Transactions in 2026
March 27, 2026
by Holding Subsidiary
March 24, 2026
Announcement on Obtaining Drug Registration Certificate by Wholly-owned Subsidiary
March 3, 2026
Announcement on Wholly-owned Sub-subsidiary Obtaining Approval for Marketing of Chemical APIs
February 24, 2026
Announcement on Proposed Selection of Partial Drugs for Continuation Procurement Under National Procurement Scheme After Agreement Expiry
February 11, 2026
Announcement on Wholly-owned Subsidiary's Passing GMP Compliance Inspection for Drugs
February 9, 2026
Announcement on Provision for Impairment
January 26, 2026
Announcement on Resolutions of the 1st Meeting of the 9th Board of Directors
December 24, 2025
Notice on Convening the 3rd Extraordinary General Meeting in 2025
December 8, 2025
Announcement on Election of Employee Director
November 21, 2025
Announcement on Attending Three-Quarter Report Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2025
November 5, 2025
Announcement on Progress in Public Listing and Transfer of Equity in a Holding Subsidiary and Completing Industrial and Commercial Change
October 31, 2025
Report for Q3 2025
October 29, 2025
Announcement on Prospective Winning of the 11th National Centralized Drug Procurement
October 28, 2025
Announcement on the Progress and Transaction Results of the Public Listing Transfer of Subsidiary Equity
October 17, 2025
Announcement on Wholly-owned Subsidiary Obtaining Approval for Marketing of Chemical APIs
October 10, 2025
Announcement on Resignation of Senior Management Members
October 9, 2025
Announcement on Resolutions of the 24th (Extraordinary) Meeting of the 8th Board of Directors
September 22, 2025
Announcement on the Voluntary Information Disclosure of Drug Passing the Consistency Evaluation for Generic Drugs
September 17, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
September 15, 2025
Announcement on the Wholly-owned Subsidiary Obtaining the Approval Notice for Drug Supplementary Application
September 12, 2025
Announcement on Implementation of Semi-annual Dividend Distribution for 2025
September 8, 2025
Notice on Convening the 2nd Extraordinary General Meeting in 2025
August 29, 2025
Announcement on Progress in Public Listing and Transfer of Equity of Holding Subsidiary
August 28, 2025
Announcement on Resignation of Senior Management Member
August 3, 2025